Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial

Short title: UC Remission and Maintenance Outcomes

David T. Rubin,* Marc Bradette,† Libor Gabalec,§ Daniela Dobru,‡ Juan Márquez,¶ Susi Inglis,# Elizabeth Magee,** Dory Solomon,** Geert D’Haens,**‡‡ on behalf of the Ulcerative Colitis Remission Study Group

*The University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, USA; †CHUQ Research Center, L’Hôtel-Dieu de Québec, Québec, Canada; §Orlickoustecka Nemocnice a.s., Department of Internal Medicine, Ústí nad Orlicí, Czech Republic; ‡University of Medicine and Pharmacy Târgu Mures, Gastroenterology Department, Târgu Mures, Romania; ††Department of Colorectal Surgery, Clínica Las Américas, Medellin, Columbia; #Shire, Basingstoke, UK; **Shire, Wayne, PA, USA; ‡‡Academic Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, the Netherlands.

Email:

David T. Rubin: drubin@medicine.bsd.uchicago.edu
Marc Bradette: marcbradette@gmail.com
Libor Gabalec: libor.gabalec@seznam.cz
Daniela Dobru: danidobru@gmail.com

© European Crohn’s and Colitis Organisation 2016. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Juan Márquez: juanmarquezv@gmail.com

Susi Inglis: susi_i@hotmail.com

Elizabeth Magee: elizabethro50@hotmail.com

Dory Solomon: dory.solomon@hotmail.com

Geert D’Haens (corresponding author): g.dhaens@amc.uva.nl

Correspondence:

Geert D’Haens, MD, PhD
Professor of Medicine and Gastroenterology
Academic Medical Centre
Meibergdreef 9
1100 DZ Amsterdam
The Netherlands
E-mail: g.dhaens@amc.uva.nl
Phone: +3120 56 63534
Fax: +3120 69 17033

Results of this analysis were previously presented in part at the 20th United European Gastroenterology Week (20-24 October, 2012, Amsterdam, The Netherlands), the 77th Annual Scientific Meeting of the American College of Gastroenterology (19-24 October, 2012, Las Vegas, NV, USA), 8th Congress of European Crohn’s and Colitis Organisation (14-16 February, 2013, Vienna, Austria), Digestive Disease Week 2013 (18-21 May, 2013, Orlando, FL), 21st United European Gastroenterology Week (12-16 October, 2013,
Berlin, Germany), the 78th Annual Scientific Meeting of the American College of Gastroenterology (11-16 October, 2013, San Diego, CA, USA), Canadian Digestive Disease Week 2014 (8-10 February, 2014, Toronto, Canada), 9th Congress of European Crohn’s and Colitis Organisation (20-22 February, 2014, Copenhagen, Denmark), and Asociación Española de Gastroenterología Meeting (26-28 March, 2014, Madrid, Spain).
**Abbreviations**

- **5-ASA**: 5-aminosalicylic acid
- **AE**: Adverse event
- **BID**: Twice-daily
- **CI**: Confidence interval
- **FoTA**: Final on-treatment assessment
- **OR**: Odds ratio
- **PGA**: Physician’s Global Assessment
- **QD**: Once-daily
- **TEAE**: Treatment-emergent adverse event
- **UC**: Ulcerative colitis
- **UC-DAI**: UC Disease Activity Index
ABSTRACT

Background and Aims: This study assessed the efficacy of maintenance treatment with multimatrix mesalazine following achievement of complete or partial remission after induction treatment with high-dose multimatrix mesalazine.

Methods: In this phase 3b/4 open-label, multicenter, prospective, single-arm study, patients with mild-to-moderate ulcerative colitis were treated with multimatrix mesalazine 4.8 g/day once daily for 8 weeks (induction phase). At Week 8, those who achieved complete or partial remission based on predefined clinical and endoscopic criteria were eligible to receive 12 months of multimatrix mesalazine 2.4 g/day once daily maintenance therapy. The primary endpoint was the proportion of patients in complete remission at Month 12.

Results: 717 patients received induction treatment; 25.9% and 39.3% of patients achieved complete and partial remission, respectively, at Week 8. A total of 461 patients entered the maintenance phase. The likelihood of remaining in/achieving complete remission at Month 12 was higher for patients who entered the maintenance phase in complete remission compared with those who began maintenance in partial remission (47.8% vs 26.0%; \( P < 0.001 \)). At Month 12, mucosal healing (endoscopy score \( \leq 1 \)) was demonstrated in 76.4% (139/182) and 63.5% (176/277) of those who were in complete and partial remission, respectively, at the end of induction.

Conclusion: Patients achieving complete remission prior to dose reduction were more likely to remain in remission at Month 12. Clinicaltrials.gov number, NCT01124149.

Keywords: 5-aminosalicylic acid (5-ASA); inflammatory bowel disease; MOMENTUM.
INTRODUCTION

Ulcerative colitis (UC) is an inflammatory disease of the large bowel characterized by relapsing and/or remitting gastrointestinal and systemic symptoms including bloody diarrhea and rectal urgency. Primary goals of UC management are induction and maintenance of disease remission including healing of the mucosa to improve patients’ health and quality of life. With no known cure for UC, most patients will need lifelong maintenance medical therapy to help prevent disease relapse. In a prospective trial by Meucci and colleagues, patients with mild-to-moderate UC relapse received induction treatment with a combination of oral and topical mesalazine. If patients were in clinical and endoscopic remission (Mayo score ≤1), the observed 1-year incidence of relapse was 23% compared with a relapse rate of 80% in patients who attained only clinical, but not endoscopic, remission. Similarly, in patients with moderate-to-severe UC relapse treated with infliximab in the ACT trials, colectomy risk was significantly lower if patients had a Mayo endoscopy subscore ≤1 than if the mucosa was more severely affected (Mayo score ≥2).

For patients with active mild-to-moderate UC, mesalazine (5-aminosalicylic acid; 5-ASA), has an established efficacy and a favorable safety profile; therefore, it has been recommended as first-line therapy. Multimatrix mesalazine is a once-daily (QD), oral formulation of 5-ASA for induction and maintenance of remission in mild-to-moderate UC. In two phase 3, placebo-controlled, double-blind, randomized studies, multimatrix mesalazine was shown to be safe and effective in the induction of complete (clinical and endoscopic) remission. A subsequent long-term maintenance study of multimatrix
mesalazine treatment demonstrated high clinical and endoscopic remission rates in a subset of patients from the combined phase 3 induction studies who had achieved complete (clinical and endoscopic) remission. A phase 4 open-label study also demonstrated efficacy of multimatrix mesalazine in maintaining quiescence in patients with UC, while another phase 3 study showed that multimatrix mesalazine was non-inferior to a twice-daily (BID) delayed-release formulation of mesalazine in endoscopic maintenance of remission.

While multimatrix mesalazine has demonstrated efficacy in induction and maintenance of remission in UC, little is currently known about the effect of the success of induction treatment on long-term outcomes. In addition, dose reduction during UC maintenance is frequently employed as a therapeutic approach to reduce the number of pills patients have to take, or it can merely be a consequence of poor adherence. This strategy has not been formally studied in a prospective fashion. This study (MOMENTUM trial; ClinicalTrials.gov Identifier: NCT01124149) was designed to determine whether patients who achieved complete remission with mucosal healing after induction therapy with multimatrix mesalamine had better long-term outcomes compared with those who attained only partial remission.
METHODS

Patients

Participants were aged ≥18 years and had an established diagnosis of UC by earlier sigmoidoscopy or colonoscopy with compatible histology or were newly diagnosed with UC. Disease activity was assessed using a modified UC-disease activity index (UC-DAI). The UC-DAI consists of 4 parameters (scored from 0-3; maximum score = 12): rectal bleeding, stool frequency, rectosigmoidoscopy, and Physician’s Global Assessment (PGA). The standard UC-DAI was modified so that an endoscopy score of 1 (mild disease) did not include friability, which was scored as 2 (moderate disease) as previously described. Eligible patients had active disease with a total modified UC-DAI of 4 to 10 with an endoscopy score ≥1 and PGA ≤2. Patients could receive stable maintenance therapy of 5-ASA ≤3.2 g/day (excluding multimatrix mesalazine), or the equivalent dose of sulfasalazine. This treatment was discontinued at study start. Pregnant women were excluded. Additional exclusion criteria included: onset of flare on mesalazine >6 weeks prior to study (no time limit for flare onset if untreated), Crohn’s disease, proctitis (inflammation extent ≤15 cm from anus), bleeding disorders, active peptic ulcer disease, asthma and known hypersensitivity to mesalazine, prior colonic surgery, moderate/severe renal and/or hepatic impairment, and prior biologic (eg, anti-tumor necrosis factor) use. Stool cultures were performed during screening, and if positive for enteric pathogens, the patient was ineligible.

The study protocol, informed consent document, and all patient recruitment information were approved by the institutional review board or independent ethics committee at each
site. The study was conducted in accordance with International Conference on Harmonisation Good Clinical Practice guidelines and local ethical and legal regulations, in line with the principles of the Declaration of Helsinki. All authors had access to study data, and reviewed and approved the final manuscript.

**Study Design**

In this phase 3b/4 open-label, multicenter, single-arm, prospective study, all enrolled patients were treated with multimatrix mesalazine 4.8 g/day QD for 8 weeks in the induction phase (Figure 1). Patients achieving complete remission or partial remission (defined below) by Week 8 were eligible to continue with 12-months of multimatrix mesalazine 2.4 g/day QD maintenance treatment. The study was conducted at 83 sites across 14 countries between June 2010 and December 2012.

Study visits occurred at screening, baseline (Week 0 of induction), Week 3 of induction, Week 8 of induction (Month 0 of maintenance), and at Months 3, 6, 9, and 12 of maintenance. Endoscopies with biopsies were performed at screening or baseline, Week 8/Month 0, and Month 12. Endoscopies were performed by the same investigator/endoscopist for scoring consistency but central independent reading was not used. Treatment compliance was measured by tablet count and was calculated for all study visits after baseline visit; patients were considered compliant if they had taken 80-120% of the prescribed/dispensed medication at each visit.
Study Objectives

The primary objective of this study was to compare proportions of patients in complete remission (defined as in prior studies of multimatrix mesalazine as a modified UC-DAI score ≤1, with a score of 0 for both rectal bleeding and stool frequency, and a ≥1-point reduction in endoscopy score from baseline)\textsuperscript{10,11,15} following 12 months of maintenance therapy between those who achieved complete remission by Week 8 of induction treatment versus those who achieved partial remission (modified UC-DAI ≤3, with a combined stool frequency and rectal bleeding score ≤1, and not in complete remission) after induction.

Secondary objectives from the induction phase included assessment of the proportion of patients in complete remission at Week 8, and assessment of symptom improvement (≥1-point reduction in rectal bleeding and stool frequency scores) at Weeks 3 and 8. Safety and tolerability during both induction and maintenance phases were also examined.

Secondary endpoints that were studied in maintenance phase, again comparing patients with complete and partial remission by Week 8, included: 1) the proportion of patients in each group who achieved clinical remission [stool frequency and rectal bleeding scores of 0] at Month 12 regardless of endoscopy; 2) the proportion of patients in each group who achieved or maintained mucosal healing [endoscopy score ≤1 on the UC-DAI] at Month 12; and 3) the time to relapse in each group [defined as the need for treatment escalation for UC including colectomy, or study withdrawal due to lack of efficacy].
Statistical Analyses

Based on remission data from prior studies, it was assumed that the proportion who would be in complete remission at Month 12 would be 65% for patients in complete remission at Month 0, and 50% for patients in partial remission at Month 0. With 80% power and a ratio of patients in complete remission to partial remission of 1.5:1, 382 patients were estimated to be necessary for inclusion in the maintenance phase. With the assumption that 55% of enrolled patients would continue into maintenance, 695 patients needed to be enrolled; it was anticipated that ~875 patients would need to be screened to enroll the required 695 patients into the study, and that 306 patients would complete through Month 12 of maintenance.

Analyses of efficacy endpoints were performed on the respective efficacy populations for the induction and maintenance phases, defined as patients who received ≥1 dose of investigational drug and had ≥1 post-dose efficacy assessment in either treatment phase. The primary endpoint analysis was performed on the maintenance phase efficacy population; all patients who did not complete the study (missing data at Month 12) were assumed not to be in remission. A sensitivity analysis of the primary endpoint was also conducted at final on-treatment assessment (FoTA), defined as data from Month 12 or an early withdrawal visit. A second sensitivity analysis of the maintenance data was conducted on the patient population with biopsies that confirmed histologically active UC at baseline (maintenance phase positive baseline biopsy population). For these analyses, the proportion of patients in complete remission at Month 12 were compared between
those who had achieved complete versus partial remission during induction using a logistic regression model with a term for remission group only.

The proportion of patients in clinical remission at Month 12 and FoTA was compared between the complete and partial remission cohorts at Month 0 for the maintenance phase efficacy population and the maintenance phase positive baseline biopsy population; these comparisons were performed using the same logistic regression model as the primary analysis. The proportions of patients who achieved or maintained mucosal healing at Month 12 and at FoTA were summarized by remission group.

Adverse event (AE) summaries for the induction and maintenance phases were conducted on all patients who had ≥1 dose of study drug (safety population) in that phase. Statistical programming and analyses of the efficacy and safety populations were performed using SAS® Version 9.1 (SAS Institute, Cary, NC, USA) or higher.
RESULTS

Patients

A total of 722 patients were enrolled from June 2010 to December 2012; 717 (99.3%) patients were treated and 639 (88.5%) patients completed the 8-week induction phase. (Figure 2). The most common reasons for early study discontinuation in the induction phase were patient withdrawal (3.0%), AEs (2.9%), and lack of efficacy (2.4%). A total of 472 (65.4%) patients were eligible to enter the maintenance phase, of whom 469 agreed to participate; patients who did not achieve either partial or complete remission were excluded. Maintenance treatment was initiated in 461 (98.3%) patients, of whom 373 (79.5%) completed the 12-month maintenance phase. The most common reasons for early withdrawal in the maintenance phase included lack of efficacy (8.5%) and AEs (5.1%). Treatment non-compliance was very low in both phases: 2.0% and 0.9% of patients in the induction and maintenance phases, respectively, consumed <80% of their prescribed medication. Baseline patient demographic and clinical characteristics are presented in Table 1; patients in the 2 maintenance groups (those with complete remission and those with partial remission following induction) were comparable with regard to baseline characteristics. A total of 49.7% of enrolled patients had prior treatment with mesalazine, and <1% had prior treatment with corticosteroids.

Efficacy

_Induction phase with multimatrix mesalazine 4.8 g/day_

At Week 8, 25.9% (186/717) of patients achieved complete remission and 39.3% (282/717) achieved partial remission. Rectal bleeding scores improved by ≥1-point in
42.4% of patients by Week 3 and 59.8% by Week 8. Stool frequency scores improved by \( \geq 1 \)-point in 38.5% and 58.9% of patients by Weeks 3 and 8, respectively. By Weeks 3 and 8, the combination of both rectal bleeding and stool frequency scores showed improvement from baseline in 25.2% and 45.3% of patients, respectively.

**Maintenance phase primary endpoint: complete remission at Month 12 with multimatrix mesalazine 2.4 g/day**

Of 182 patients in complete remission at Month 0 of the maintenance phase, 87 (47.8%) remained in complete remission at Month 12; of 277 patients in partial remission at Month 0, 72 (26.0%) achieved complete remission at Month 12. The odds ratio (OR) of complete remission to partial remission was 2.61 (95% confidence interval [CI]: 1.76, 3.87), and the difference between the 2 groups was statistically significant \( P < 0.001 \). Sensitivity analyses were consistent with the primary endpoint analysis. At FoTA, 48.9% of patients in complete remission at Month 0 were in complete remission at Month 12, compared with 26.4% in partial remission at Month 0 (OR, 2.67; 95% CI: 1.80, 3.97; \( P < 0.001 \)). For the maintenance phase positive baseline biopsy population, 45.3% of patients in complete remission at Month 0 were in complete remission at Month 12, compared with 25.0% in partial remission at Month 0 (\( P < 0.001 \)).

**Secondary endpoints**

Looking at clinical remission only, 58.8% (107/182) of patients who had been in complete remission at Month 0 were in clinical remission at Month 12, compared with 40.4% (112/277) of patients in partial remission at Month 0 (\( P < 0.001 \)). The difference
between groups for clinical remission was smaller than that for complete remission, where endoscopy is included in the remission definition. Sensitivity analyses at FoTA and for the positive baseline biopsy population were consistent with this result.

Symptom scores at baseline, Month 0, and Month 12 are shown in Figure 3. For those in complete remission at Month 0, by definition, 100% had rectal bleeding and stool frequency scores of 0 at Month 0; at Month 12, 65.4% and 62.6% of these patients, respectively, had maintained rectal bleeding and stool frequency scores of 0. For those in partial remission at Month 0, 88.8% and 41.9% of patients, respectively, had rectal bleeding and stool frequency scores of 0 at Month 0; at Month 12, 57.0% and 42.6% of this group had rectal bleeding and stool frequency scores of 0.

The proportions of patients with mucosal healing (endoscopy score ≤1) at Month 12 were 76.4% and 63.5%, respectively, for those in complete versus partial remission at Month 0 (nominal \( P =0.0037 \)). Endoscopy scores after 12 months of maintenance therapy with multimatrix mesalazine are shown in Figure 4. Relapse rates at Month 12 were 6.0% and 10.5%, respectively, for those in complete and partial remission at Month 0. Among the patients who had relapsed, the median time to relapse was 176 days for those who achieved complete remission at Month 0 (n = 11), and 148 days for patients in partial remission at Month 0 (n = 29).
Safety

During induction, 202 (28.2%) patients experienced ≥1 treatment-emergent AE (TEAE). The most commonly reported TEAE was headache (2.1%). In the maintenance phase, TEAEs were less frequent in the complete versus partial remission group. Overall, 68/183 (37.2%) patients in complete remission at Month 0 and 139/278 (50.0%) patients in partial remission at Month 0 reported ≥1 TEAE (Table 2). The most common TEAEs during maintenance were UC, headache, bronchitis, influenza, nasopharyngitis, and back pain. The frequency of TEAEs was generally low, and most TEAEs were mild or moderate in severity.

During induction, 47 patients experienced 61 TEAEs that led to study withdrawal; the events most frequently leading to withdrawal were lack of efficacy (n = 24; 3.3%), UC (n = 9; 1.3%), and diarrhea (n = 3; 0.4%). In the maintenance phase, the proportion of patients experiencing TEAEs leading to withdrawal was almost twice as high in the partial remission group (15.1%) than in the complete remission group (8.2%). For those in partial remission at Month 0, the events most frequently leading to withdrawal were lack of efficacy (n = 18; 6.5%) and UC (n = 17; 6.1%); for those in complete remission at Month 0, the most frequently reported TEAE leading to withdrawal was UC (n = 10; 5.5%).

During induction, 13 (1.8%) patients reported 14 serious TEAEs. Three were considered by the investigator to be related to the study drug: UC exacerbation (n = 1), acute pancreatitis (n = 1), and lung infection (n = 1). These patients were discontinued from
the study, and the events subsequently resolved. During maintenance, 14 patients experienced 17 serious TEAEs, of which 1 (worsening diarrhea) was considered related to study drug. The event resolved and the patient completed the study. One patient died following a cerebrovascular incident during the maintenance phase, which was considered unrelated to the study drug.

**DISCUSSION**

This prospective study is the first to examine the scheduled dose reduction of 5-ASA in UC patients. We explored maintenance outcomes in patients with UC treated with an induction regimen of multimatrix mesalazine 4.8 g/day, then switched to maintenance phase at 2.4g/day. The primary endpoint was met, as a significantly higher proportion of patients in complete versus partial remission at the start of the maintenance phase were in complete remission 12 months later. These results were supported by sensitivity analyses on the primary endpoint, as well as results from the maintenance phase secondary endpoint analyses.

Our study indicates that the outcomes following mesalazine induction are predictive of long-term outcome. Half of the patients who achieved complete remission during induction with high-dose multimatrix mesalazine were able to maintain complete remission after 12 months of treatment with a reduced dosage, a success rate almost twice as high as in the patients entering maintenance in partial remission. Nonetheless, 1 in 4 patients attaining partial remission after induction reached complete remission 12 months later. In addition, >40% of patients in the partial remission group had symptom scores of
0 at Month 12, and >60% of patients in the partial remission group demonstrated mucosal healing at Month 12. It is possible that some of the observed difference between the groups is due to overlap of bowel irritability; this is a common challenge in symptom-based assessments of disease activity in UC. However, non-symptom-based measures (eg, endoscopy) also resulted in significant group differences, suggesting that underlying inflammation was a primary factor in differentiation. These findings highlight the importance of long-term mesalazine treatment for patients with UC, and suggest that, contrary to previous and non-evidence-based assertions, 2.4 g/day of multimatrix mesalazine during maintenance may be beneficial for both those in complete and partial remission following induction at higher doses.

It is well appreciated that both patients and physicians dose reduce mesalazine while in maintenance phase. This study showed that complete remission was a significant predictor of successful dose reduction in the maintenance phase; patients attaining that endpoint may be most suitable for this strategy. Conversely, patients without complete remission, including mucosal healing, would probably benefit from an additional period of high dose mesalazine treatment, additional topical treatment, or even escalation to other classes of therapies. These patients may also benefit from combination treatment with aminosalicylate enemas and potentially topical or even oral corticosteroids.

There are studies that have explored the benefit of higher dose mesalazine for maintenance, and we believe that these studies add information regarding potential treatment considerations for with a more complex disease course, who have not achieved
complete remission within 8 weeks, or who relapse after dose reduction. The continued use of high-dose mesalazine is supported by a recent retrospective study that examined the efficacy of 4.0 g/day maintenance therapy with mesalazine (PENTASA®) in Japanese UC patients who had achieved clinical improvement or remission; in this study, fewer patients who received long-term (>105 days) versus short-term (≤105 days) maintenance treatment relapsed (29.8% vs 48.3%; \( P <0.05 \)), and the median time to relapse was also longer in the long-term treatment group. Another retrospective study comparing low (2.4-2.8 g/day) versus high dose (4.4-4.8 g/day) mesalazine maintenance treatment among UC patients found no significant differences in flare risk between groups when adherence to medication was high or moderate, suggesting that adherence may be more important for reducing flare risk than the dose used for maintenance therapy. The importance of achieving mucosal healing for long-term outcomes is supported by the results of a study by Meucci and colleagues, who demonstrated that patients achieving clinical but not endoscopic remission following 6-week oral (4 g/day) and topical (2 g/day) mesalazine treatment achieved significantly higher cumulative relapse rates after 1 year compared with those who achieved both clinical and endoscopic remission (80% vs 23%; \( P <0.0001 \)).

Another implication of our study findings for clinical practice is that endoscopic assessment appears to play a pivotal part in patient management, since it is an essential tool to evaluate the mucosa and guide the clinician to reach the treatment target of mucosal healing. Future mesalazine studies should explore dynamic and repeated interval dosing to allow for treatment adjustments based on long-term clinical and
endoscopic stability. For example, it is unclear whether those in partial remission could
benefit from a longer cycle of high-dose induction, or whether those on 2.4 g/day
maintenance treatment who flare could benefit from a short interval of increased
mesalazine dosing post-relapse.

The safety results from both the induction and maintenance phases indicated that
multimatrix mesalazine was well tolerated. Types and frequencies of TEAEs were
similar between complete and partial remission groups. The safety profile was consistent
with previous multimatrix mesalazine clinical studies, and no new safety signals were
identified. In prior phase 3 induction studies\textsuperscript{10,11} as well as the associated maintenance
study,\textsuperscript{12} the safety profile of multimatrix mesalazine was similar to that of the placebo
arms in the induction studies.\textsuperscript{10,11} In the prior induction studies (combined analysis), the
proportion of patients experiencing TEAEs was 32.4\% for those on multimatrix
mesalazine 4.8 g/day, with headache being the most commonly reported (3.4\%).\textsuperscript{18} By
comparison, in the induction phase of the current study, 28.2\% of patients on multimatrix
mesalazine reported TEAEs, with headache again being the most commonly reported
(2.1\%). In the prior phase 3 maintenance study, 37.9\% of patients experienced TEAEs,
mostly of mild or moderate intensity. The most commonly reported TEAEs were
worsening UC (10.7\% and 7.7\% in the 2.4 g/day single and divided dose cohorts,
respectively) and gastrointestinal disorders.\textsuperscript{12} In the maintenance phase of the current
study, 37.2\% of those in complete remission at Month 0 reported TEAEs, with UC
(7.7\%) being most commonly reported.
Some limitations of the study include that this was an open-label study without a placebo control, which may have introduced sampling bias into the results. Also, the subjective component of the UC-DAI score may have introduced variability between investigator assessments, and subsequent classification of patients who are in endoscopic remission. Additionally, it remains unclear how prior mesalazine dosing affected the long-term outcomes of these patients, as study patients could have received up to 3.2 g/day mesalazine prior to study entry. Finally, we did not use independent assessment of endoscopic recordings, an approach that has recently become standard in modern UC trials, but was not yet common practice at the start of this study. As the same endoscopist performed both procedures in the patient, this may have introduced unconscious bias related to improvements. However, the blinding and randomization design may have ameliorated this limitation.

The data obtained from the current study confirm that long-term maintenance with multimatrix mesalazine is safe and efficacious in patients with mild-to-moderate UC. Those who begin maintenance treatment in complete remission have improved long-term outcomes compared with those who begin maintenance treatment in partial remission.

FUNDING

This work was supported by Shire Development LLC.
CONFLICTS OF INTEREST

David Rubin has received financial support for research from AbbVie, Elan, Warner Chilcott, and Prometheus; received lecture fees from Merck; and consulted for AbbVie, Janssen, UCB, Elan, Shire, Exagen, Prometheus, and Takeda. Marc Bradette, Libor Gabalec, Daniela Dobru, and Juan Márquez have no conflicts of interest to declare. Susi Inglis is a former statistical consultant for Shire, Basingstoke, United Kingdom. Elizabeth Magee is a former employee of Shire, Wayne, PA, USA and owns stock and/or stock options in Shire. Dory Solomon is a former employee of Shire, Wayne, PA, USA. Geert D’Haens has received financial support for research from AbbVie, Janssen Biologics, Given Imaging, MSD, Dr Falk Pharma, and PhotoPill; received lecture fees from AbbVie, Tillotts, Tramedico, Ferring, MSD, UCB, Norgine, and Shire; and consulted for AbbVie, Actogenix, Centocor, Cosmo, enGene, Ferring Pharmaceuticals, GlaxoSmithKline, Janssen Biologics, Millenium Pharmaceuticals, MSD, Novo Nordisk, PDL BioPharma, Pfizer, SetPoint, Shire, Takeda, Teva, and UCB.
ACKNOWLEDGEMENTS

Dr. Sandeep Nijhawan is acknowledged for his contributions to this study.

Writing assistance:

Under the direction of the authors, Wilson Joe, of MedErgy, provided writing assistance for this manuscript. Editorial assistance in formatting, proofreading, copy editing, and fact checking was also provided by MedErgy. Representatives from Shire also reviewed and edited this manuscript for scientific accuracy. Shire Development LLC, the study sponsor, provided funding to MedErgy for support in writing and editing this manuscript. Although the sponsor was involved in the design, collection, analysis, interpretation, and fact checking of information, the content of this manuscript, the ultimate interpretation, and the decision to submit it for publication in *Journal of Crohn’s and Colitis* was made by all authors.

Author contributions:

All authors participated in drafting of the manuscript or critical revision of the manuscript for important intellectual content and provided approval of the final submitted version. Individual contributions are as follows:

**DR:** Study design; analysis and interpretation of data; principal investigator; guarantor

**MB:** Patient recruitment; study site supervision

**LG:** Patient recruitment; study site supervision; interpretation of data

**DD:** Study site supervision

**JM:** Patient recruitment; study site supervision; interpretation of data
SI: Study design; data collection; statistical analysis and interpretation

EM: Study concept and design; data analysis and interpretation

DS: Study concept and design; study supervision; data analysis and interpretation

GDH: Study design; analysis and interpretation of data; principal investigator; guarantor

All members of the Ulcerative Colitis Remission Study Group, listed below by country, assisted in patient recruitment, data collection, and study site supervision: Belgium (Filip Baert, Geert D’Haens, Francois D’Heygere); Canada (Marc Bradette, John Marshall, Michael Ostro, Pierre Pare); Colombia (Jacobo Feris, Fabian Juliao, Alejandro Orozco, Juan Márquez); Czech Republic (Marek Benes, Vladimir Compel, Ladislav Douda, Libor Gabalec, Jan Hejcmam, Jana Kozeluhova, Milan Lukas, Vladimir Nosek, Michal Tichy, Tomas Vanasek); France (Arnaud Bourreille, Frank Zerbib); Germany (Torsten Kucharzik); Hungary (Andor Grenda, Zoltan Gurzo, Gyula Pecsi, Tibor Szaloki); India (Rupa Banerjee, Prashant Bhandarkar, Abhijit Chandra, Bhabadev Goswami, Mukesh Kalla, Sanjay Kolte, Rupesh Bhaidas Mehta, Palakurthi Murali Krishna, Sandeep Nijhawan, K. T. Shenoy, Ajit Sood, B. Vishwanath Tantry, Vinay Thorat); Ireland (Hugh Mulcahy, Colm O’Morain, Stephen Patchett); Poland (Marcin Hanczewski, Marek Horynski, Robert Petryka, Wojciech Piotrowski, Jerzy Rozciecha, Marek Skoczylas); Romania (Dan Andronescu, Christian Banciu, Daniela Dobru, Liliana Gheorghe, Adrian Goldis, Victor Stoica); South Africa (Nazimbuddin Aboo, Frederick Bester, Suleman Moola, Maarten Prins, Christo van Rensburg, John Wright); Spain (Javier P. Gisbert); United Kingdom (Simon Travis); United States (Humberto Aguilar, Richard Altman, Raj Bhandari, George Catinis, Sreenivas Chintalapani, Steven Desautels, M. Emin Donat,
Michael Epstein, Syam Gaddam, Daniel Geenen, Lev Ginzburg, Lawrence Goldberg,
Douglas Homoky, M. Mazen Jamal, Michael Kreines, Michael LeVine, Edward Loftus,
Stephen Minton, Mark Nagrani, Vijay Narayan, Vijayalakshmi Pratha, Charles Randall,
David Rubin, Peter Winkle, Douglas Wolf, Salam Zakko).
References


FIGURE LEGENDS

Figure 1. Study design.

QD, once daily; 5-ASA, 5-aminosalicylic acid.

Figure 2. Patient flow diagram.

Figure 3. (A) Rectal bleeding scores and (B) stool frequency scores at baseline, Month 0, and Month 12 among patients who achieved complete or partial response at Month 0.\(^a\)

\(^a\)Maintenance phase efficacy population (n = 459); percentages at Month 12 do not add up to 100% due to the absence of scores from patients who discontinued the study prior to Month 12.

Figure 4. Endoscopy scores at baseline, Month 0, and Month 12 among patients who achieved complete or partial response at Month 0.\(^a\)

\(^a\)Maintenance phase efficacy population (n = 459); percentages at Month 12 do not add up to 100% due to the absence of scores from patients who discontinued the study prior to Month 12.
Table 1. Baseline Patient Demographic and Clinical Characteristics

<table>
<thead>
<tr>
<th>Characteristic, n (%)</th>
<th>Induction phase (N = 717)</th>
<th>Maintenance phase (N = 461)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Age, mean (SD), years</strong></td>
<td>42.9 (13.97)</td>
<td>42.7 (14.26)</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>409 (57.0)</td>
<td>260 (56.4)</td>
</tr>
<tr>
<td>Female</td>
<td>308 (43.0)</td>
<td>201 (43.6)</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>428 (59.7)</td>
<td>256 (55.5)</td>
</tr>
<tr>
<td>Non-White</td>
<td>289 (40.3)</td>
<td>205 (44.5)</td>
</tr>
<tr>
<td>Black/African American</td>
<td>10 (1.4)</td>
<td>7 (1.5)</td>
</tr>
<tr>
<td>Asian</td>
<td>206 (28.7)</td>
<td>143 (31.0)</td>
</tr>
<tr>
<td>American Indian/Alaska Native</td>
<td>13 (1.8)</td>
<td>12 (2.6)</td>
</tr>
<tr>
<td>Other</td>
<td>60 (8.4)</td>
<td>43 (9.3)</td>
</tr>
<tr>
<td><strong>UC history</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>How was UC first established?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sigmoidoscopy</td>
<td>260 (36.3)</td>
<td>179 (38.8)</td>
</tr>
<tr>
<td>Colonoscopy</td>
<td>566 (78.9)</td>
<td>357 (77.4)</td>
</tr>
<tr>
<td>Barium enema</td>
<td>18 (2.5)</td>
<td>11 (2.4)</td>
</tr>
<tr>
<td>Compatible histology</td>
<td>713 (99.4)</td>
<td>460 (99.8)</td>
</tr>
<tr>
<td>Full extent of disease &gt;15 cm</td>
<td>714 (99.6)</td>
<td>461 (100)</td>
</tr>
</tbody>
</table>

Classification of extent of disease
<table>
<thead>
<tr>
<th>Health Status</th>
<th>Value 1</th>
<th>Value 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left-sided</td>
<td>557 (77.7)</td>
<td>359 (77.9)</td>
</tr>
<tr>
<td>Involvement of transverse colon</td>
<td>50 (7.0)</td>
<td>33 (7.2)</td>
</tr>
<tr>
<td>Pancolitis</td>
<td>110 (15.3)</td>
<td>69 (15.0)</td>
</tr>
<tr>
<td>Rectal involvement</td>
<td>653 (91.1)</td>
<td>420 (91.1)</td>
</tr>
<tr>
<td>Mean (SD) time since current acute episode, days $^C$</td>
<td>38.6 (179.22)</td>
<td>42.4 (218.61)</td>
</tr>
<tr>
<td>Number of newly diagnosed patients</td>
<td>70 (9.8)</td>
<td>38 (8.2)</td>
</tr>
<tr>
<td>Mean (SD) duration since diagnosis, months $^{D,E}$</td>
<td>71.2 (86.56)</td>
<td>69.8 (80.49)</td>
</tr>
<tr>
<td>No. acute episodes in last year $^E$</td>
<td>72 (10.0)</td>
<td>50 (10.8)</td>
</tr>
<tr>
<td>0</td>
<td>479 (66.8)</td>
<td>320 (69.4)</td>
</tr>
<tr>
<td>1-2</td>
<td>86 (12.0)</td>
<td>48 (10.4)</td>
</tr>
<tr>
<td>3-4</td>
<td>4 (0.6)</td>
<td>2 (0.4)</td>
</tr>
<tr>
<td>5-6</td>
<td>4 (0.6)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>≥7</td>
<td>2 (0.3)</td>
<td>2 (0.4)</td>
</tr>
<tr>
<td>No. acute episodes since diagnosis $^E$</td>
<td>16 (2.2)</td>
<td>10 (2.2)</td>
</tr>
<tr>
<td>0</td>
<td>247 (34.4)</td>
<td>164 (35.6)</td>
</tr>
<tr>
<td>1-2</td>
<td>177 (24.7)</td>
<td>115 (24.9)</td>
</tr>
<tr>
<td>3-4</td>
<td>74 (10.3)</td>
<td>51 (11.1)</td>
</tr>
<tr>
<td>5-6</td>
<td>125 (17.4)</td>
<td>79 (17.1)</td>
</tr>
<tr>
<td>≥7</td>
<td>8 (1.1)</td>
<td>4 (0.9)</td>
</tr>
<tr>
<td>Missing</td>
<td>2 (0.3)</td>
<td>2 (0.4)</td>
</tr>
</tbody>
</table>
Mean (SD) duration of past acute episode, days^E

|           | 32.7 (37.47) | 33.5 (41.71) |

SD, standard deviation; UC, ulcerative colitis.

^ASafety populations for induction and maintenance phases, respectively.

^BDemographic and baseline characteristics were similar between patients in complete remission at Month 0 and patients in partial remission at Month 0 in the maintenance phase.

^CMultiple procedures may have been used to establish first diagnosis of UC.

^DRelative to screening.

^EOnly for patients who were not newly diagnosed.
Table 2. TEAEs Reported in the Maintenance Phase

<table>
<thead>
<tr>
<th>Event, n (%)</th>
<th>Complete remission (n = 183)</th>
<th>Partial remission (n = 278)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any TEAE</td>
<td>68 (37.2)</td>
<td>139 (50.0)</td>
</tr>
<tr>
<td>Any severe TEAE</td>
<td>3 (1.6)</td>
<td>12 (4.3)</td>
</tr>
<tr>
<td>Any serious TEAE</td>
<td>4 (2.2)</td>
<td>10 (3.6)</td>
</tr>
<tr>
<td>Any drug-related TEAE</td>
<td>7 (3.8)</td>
<td>24 (8.6)</td>
</tr>
<tr>
<td>Any serious drug-related TEAE</td>
<td>0</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Any TEAE leading to drug discontinuation</td>
<td>15 (8.2)</td>
<td>42 (15.1)</td>
</tr>
<tr>
<td>Any TEAE leading to death</td>
<td>0</td>
<td>1 (0.4)</td>
</tr>
</tbody>
</table>

TEAEs reported in >1% of patients

<table>
<thead>
<tr>
<th>Event</th>
<th>Complete remission</th>
<th>Partial remission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ulcerative colitis</td>
<td>14 (7.7)</td>
<td>29 (10.4)</td>
</tr>
<tr>
<td>Headache</td>
<td>6 (3.3)</td>
<td>10 (3.6)</td>
</tr>
<tr>
<td>Bronchitis</td>
<td>6 (3.3)</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>5 (2.7)</td>
<td>6 (2.2)</td>
</tr>
<tr>
<td>Influenza</td>
<td>3 (1.6)</td>
<td>8 (2.9)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3 (1.6)</td>
<td>5 (1.8)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>3 (1.6)</td>
<td>5 (1.8)</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>3 (1.6)</td>
<td>4 (1.4)</td>
</tr>
<tr>
<td>Rectal bleeding</td>
<td>3 (1.6)</td>
<td>3 (1.1)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>3 (1.6)</td>
<td>2 (0.7)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>3 (1.6)</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Condition</td>
<td>Safety pop</td>
<td>TEAE</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>------------</td>
<td>------</td>
</tr>
<tr>
<td>Back pain</td>
<td>2 (1.1)</td>
<td>6 (2.2)</td>
</tr>
<tr>
<td>Frequent bowel movements</td>
<td>2 (1.1)</td>
<td>4 (1.4)</td>
</tr>
<tr>
<td>Herpes zoster</td>
<td>2 (1.1)</td>
<td>0</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>2 (1.1)</td>
<td>0</td>
</tr>
<tr>
<td>Cough</td>
<td>2 (1.1)</td>
<td>0</td>
</tr>
<tr>
<td>Anaemia</td>
<td>1 (0.5)</td>
<td>5 (1.8)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>1 (0.5)</td>
<td>4 (1.4)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>1 (0.5)</td>
<td>3 (1.1)</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>0</td>
<td>4 (1.4)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>0</td>
<td>3 (1.1)</td>
</tr>
<tr>
<td>Uveitis</td>
<td>0</td>
<td>3 (1.1)</td>
</tr>
<tr>
<td>Aphthous stomatitis</td>
<td>0</td>
<td>3 (1.1)</td>
</tr>
<tr>
<td>Toothache</td>
<td>0</td>
<td>3 (1.1)</td>
</tr>
<tr>
<td>Rash</td>
<td>0</td>
<td>3 (1.1)</td>
</tr>
</tbody>
</table>

TEAE, treatment-emergent adverse event.

SAFETY POPULATION.
Figure 1

8-week induction phase
multimatrix mesalazine 4.8 g/d QD

12-month maintenance phase
multimatrix mesalazine 2.4 g/d QD

Relapse on any 5-ASA maintenance therapy up to 3.2 g/d (excluding multimatrix) or newly diagnosed

Endoscopy

Wk 0 Wk 3 Wk 8/Mo 0

Complete remission

Partial remission

Endoscopy

Mo 3 Mo 6 Mo 9 Mo 12

Primary endpoint
Figure 2

Assessed for eligibility (n = 894)

Enrolled into induction phase (N = 722)
- Treated during induction phase (multimatrix mesalazine 4.8 g/d; n = 717)

Competed 8-week induction phase (n = 639)
- Eligible to enter maintenance phase (achieved partial or complete remission; n = 472)
- Not eligible (did not achieve remission; n = 167)
  - Discontinued induction treatment (n = 83)
    - Patient withdrawal (n = 22)
    - Adverse event (n = 21)
    - Lack of efficacy (n = 17)
    - Protocol violation (n = 14)
    - Other (n = 7)
    - Lost to follow-up (n = 2)

Entered into maintenance phase (n = 469)
- Treated during maintenance phase (multimatrix mesalazine 2.4 g/d; n = 461)

Completed 12-month maintenance phase (n = 373)
- Discontinued maintenance treatment (n = 96)
  - Lack of efficacy (n = 40)
  - Adverse event (n = 24)
  - Lost to follow-up (n = 15)
  - Protocol violation (n = 5)
  - Other (n = 2)
Figure 3A

Rectal bleeding score

Figure 3B

Stool frequency score
Figure 4

![Graph showing endoscopy scores at baseline, Month 0, and Month 12. The graph compares complete remission and partial remission at Month 0.](image-url)